ClinicalTrials.gg
RecruitingNCT06731868Updated Jan 22, 2025

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

A Phase 1/2 interventional study of LPM3770164 sustained release tablet 5 mg and LPM3770164 sustained release tablet 10 mg in Tardive Dyskinesia (TD), sponsored by Luye Pharma Group Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Luye Pharma Group Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Tardive Dyskinesia with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Tardive Dyskinesia · China.

Started
2025
with 1 other
Phase 1/2
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
4 of 10
Luye Pharma Group Ltd.

Among the 10 studies in Tardive Dyskinesia with a site in China, this one is one of 2 that started in 2025, is the only one in phase 1/2, and was the 8th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

3 of the 10 studies in Tardive Dyskinesia with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Tardive Dyskinesia with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets in TD patients.

03

Conditions studied

  • Tardive Dyskinesia (TD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who voluntarily participate in and sign the form;
  2. Male or female subjects aged ≥ 18 years and \< 65 years;
  3. (BMI) 18.5 \~ 38.0 kg/m2 (including boundary value);
  4. Subjects with a past diagnosis of schizophrenia, schizoaffective disorder, bipolar and related disorders, depressive disorders based on medical history, and stable for at least 1 month;
  5. Subjects who have been diagnosed with medication-induced TD, and whose symptoms have lasted for at least 3 months according to the ; and TD is assessed as moderate or severe (AIMS Item 8 score ≥3);
  6. Medications for schizophrenia, schizoaffective disorder, bipolar and related disorders, depressive disorders and extrapyramidal reactions should be kept dose stable for at least 1 month (benzodiazepines should stable at least 14 days, Long-acting injection should stable for at least 3 months);
  7. Females of have a negative pregnancy test. Male and female patients of childbearing potential and their spouses/partners agree to not plan to become pregnant (including the plan for sperm and egg donation) and to use effective measures throughout the study and for at least 1 month after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Has comorbid abnormal involuntary movement(s) that is more prominent than TD as judged by the investigator;
  2. Has Simpson-Angus Scale (SAS) score≥ 3 on two or more items other than items 8 and 10;
  3. Currently in the acute phase of mental disorder or severe psychiatric symptoms, unable to cooperate with the treatment and assessment, as judged by the investigator;
  4. Has a history of suicide attempt or Question 4 or Question 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) as "Yes" within the past 6 months;
  5. Has a history of neuroleptic-related malignant syndrome;
  6. Has diagnosed with malignant tumor within 3 years before randomization;
  7. Has a history of long syndrome or tachyarrhythmia within 3 years before randomization;
  8. QTcF > 450 ms, or other ECG findings in the opinion of the investigator;
  9. Patients with significant abnormal liver and kidney function indicators, meeting any of the following criteria: serum creatinine > 1.5 × (ULN); serum (ALT) or aspartate transaminase (AST) > 2.5 × ULN; total > 1.5 × ULN;
  10. Has active, severe and unstable cerebrovascular, liver, kidney, endocrine, cardiovascular, gastrointestinal, respiratory, or metabolic disorders within 30 days prior to screening, in the judgment of the investigator, would interfere with the patient's ability to participate in the trial;
  11. Any surgical condition or condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects participating in the trial, such as but not limited to history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, gastrointestinal bleeding;
  12. Has a known history of allergy to any component of the product or similar drugs, or allergic constitution;
  13. Has a positive antibody (HIV-Ab) and syphilis;
  14. Has a positive urine drug screen;
  15. Patients diagnosed with substance-related and addictive disorders (except tobacco- or caffeine-related disorders) within 6 months prior to the screening visit;
  16. Has participated in any clinical trials of drugs (excluding vitamins and minerals) within 3 months prior to the screening visit;
  17. Patients who previously received deep brain stimulation (DBS), or received electroconvulsive therapy (ECT) or other physical therapy within 1 month prior to the screening visit;
  18. Patients who use of strong inducers or inhibitors of within 14 days or 5 half-lives, whichever is longer, prior to randomization;
  19. Known history of a nonresponder to tetrabenazine, deutetrabenazinen, or valbenazine for the treatment of TD;
  20. Patients who have been injected with botulinum toxin in the past 3 months;
  21. Patients who have used the prohibited drugs in the past 1 month;
  22. Nursing mothers;
  23. For patients with schizophrenia and schizoaffective disorder, has a total PANSS score > 80, and/or a total CDSS score > 10;
  24. For patients with bipolar and related disorders or depressive disorders, has a history of rapid cycling, or a total MADRS score > 22, or a total YMRS score > 12;
  25. Other conditions judged by the investigator as unsuitable for participating in the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    LPM3770164 sustained release tablet 5 mg

    Drug: LPM3770164 sustained release tablet 5 mg

  • Experimental
    LPM3770164 sustained release tablet 10 mg

    Drug: LPM3770164 sustained release tablet 10 mg

  • Experimental
    LPM3770164 sustained release tablet 20 mg

    Drug: LPM3770164 sustained release tablet 20 mg

  • Placebo comparator
    Placebo

    Drug: LPM3770164 sustained release tablet simulant

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse event

    Number of participants with treatment-emergent adverse event will be summarized by Group, System Organ Classification (SOC), Preferred Term (PT), severity and the relationship with treatment.

    Time frame: From baseline to Week 8

  2. Change in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score

    Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

    Time frame: From baseline to Week 8

Secondary outcomes

  1. The proportion of subjects who have a 50% improvement in AIMS Dyskinesia Total Score

    Time frame: From baseline to Week 8

  2. Clinical Global Impression - Global Improvement of TD (CGI-TD)

    Time frame: From Week 2 to Week 8

  3. Patient Global Impression of Change (PGIC)

    Time frame: From Week 2 to Week 8

  4. Maximum observed concentration (Cmax)

    Time frame: From predose to 24 hours of day 1

  5. Area Under the Curve from time 0 to 24 hours of day 1 (AUC0-24h)

    Time frame: From predose to 24 hours of day 1

  6. Concentration at the end of the dosing interval at steady state (Cτ,ss)

    Time frame: Predose on Day 14±2, Day 28±2 and Day 42±2

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Oct 2025, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Oct 31, 2025
CompletionEst.
Oct 31, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06731868
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Jan 14, 2025
Primary completion
Oct 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Jan 22, 2025

Study contacts

Hufang Li
Contact
lhlh_5@163.com
+8618017311256

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LPM3770164

Start the discussion